SCHEMBL5022271

SCHEMBL5022271

CCOC(=O)C1CCN(c2c(F)cc(C(=O)O)cc2F)CC1

nearest known ligand 0.56

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.56
SMN1; SMN2 Q16637 2/20 0.52
TDP1 Q9NUW8 1/20 0.52
MAPK1 P28482 1/20 0.52
KDM4E B2RXH2 2/20 0.50
LGMN Q99538 1/20 0.50
POLB P06746 2/20 0.49
MAPT P10636 2/20 0.49
TP53 P04637 1/20 0.49
HPGD P15428 1/20 0.48
TSHR P16473 3/20 0.48
SHMT2 P34897 1/20 0.47
RECQL P46063 1/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13125313 0.93 TSHR (0.53) ALDH1A1SMN1; SMN2TDP1MAPK1KDM4E
SCHEMBL14804174 0.90 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2TDP1MAPK1KDM4E
SCHEMBL23582571 0.88 MAPT (0.56) ALDH1A1SMN1; SMN2TDP1MAPK1KDM4E
SCHEMBL10148315 0.84 FFAR4 (0.50)
SCHEMBL5025161 0.83 MAPT (0.51) ALDH1A1SMN1; SMN2TDP1MAPK1KDM4E
SCHEMBL5022411 0.82 ALDH1A1 (0.60) ALDH1A1SMN1; SMN2TDP1MAPK1KDM4E
SCHEMBL14804205 0.82 KDM4E (0.64) ALDH1A1SMN1; SMN2TDP1MAPK1KDM4E
SCHEMBL13125258 0.82 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2TDP1MAPK1KDM4E
SCHEMBL9831919 0.80 ALDH1A1 (0.60) ALDH1A1SMN1; SMN2TDP1MAPK1KDM4E
SCHEMBL13125292 0.79 CYP3A4 (0.49) ALDH1A1SMN1; SMN2TDP1KDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8765764-B2 2-acylaminothiazole derivative or salt thereof ASTELLAS PHARMA, INC. (JP) 2014-07-01 US disclosed
US-20130079351-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA, INC. (JP) 2013-03-28 US disclosed
US-8338429-B2 2-acylaminothiazole derivative or salt thereof ASTELLAS PHARMA, INC. (JP) 2012-12-25 US disclosed
US-8338429-B2 2-acylaminothiazole derivative or salt thereof ASTELLAS PHARMA, INC. (JP) 2012-12-25 US disclosed
US-20100222329-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2010-09-02 US disclosed
US-20100222329-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2010-09-02 US disclosed
US-20100222361-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2010-09-02 US disclosed
US-20100222361-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2010-09-02 US disclosed
US-7638536-B2 N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-3-fluoro-4-hydroxybenzamide; nonpeptide c-mpl ligand; low immunogenicity; proliferate human c-mpl-Ba/F3 cells; increase platelets by promoting the formation of megakaryocytic colonies; orally ASTELLAS PHARMA INC. (JP) 2009-12-29 US disclosed
US-7638536-B2 N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-3-fluoro-4-hydroxybenzamide; nonpeptide c-mpl ligand; low immunogenicity; proliferate human c-mpl-Ba/F3 cells; increase platelets by promoting the formation of megakaryocytic colonies; orally ASTELLAS PHARMA INC. (JP) 2009-12-29 US disclosed
US-7361658-B2 1-{3-chloro-5-[(4-(4-chlorothiophen-2-yl)-5-{[cyclobutyl(methyl)amino]methyl}thiazol-2-yl)carbamoyl]-2-pyridyl)piperidine-4-carboxylic acid; non-peptide thrombopoietin receptor (c-mpl-Ba/F3) ligand; less immunogenicity; platelet activator based on megakaryocyte colony; thrombocytopenia; orally ASTELLAS PHARMA INC. (JP) 2008-04-22 US disclosed
US-20060194844-A1 2-Acylaminothiazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2006-08-31 US disclosed
EP-1647553-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF Astellas Pharma Inc. (JP) 2006-04-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194844-A1 2-Acylaminothiazole derivative or salt thereof MPL, JAK2, MATK ALDH1A1 2150/4885SMN1; SMN2 1103/4885TDP1 4697/4885
US-20130079351-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF MPL, JAK2, ABL1 ALDH1A1 2060/4885SMN1; SMN2 967/4885TDP1 4760/4885
US-20100222329-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF MPL, JAK2, ABL1 ALDH1A1 2060/4885SMN1; SMN2 967/4885TDP1 4760/4885
US-20100222361-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF MPL, JAK2, ABL1 ALDH1A1 2060/4885SMN1; SMN2 967/4885TDP1 4760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.